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Abstract 
 
Alterations in lipid metabolism in cancer cells impact cell structure, signaling, and energy metabolism, 
making lipid metabolism a potential diagnostic marker and therapeutic target. In this study, we combined 
positron emission tomography (PET), desorption electrospray ionisation-mass spectrometry (DESI-MS), non-
imaging MS, and transcriptomic analyses to interrogate changes in lipid metabolism in a transgenic zebrafish 
model of oncogenic RAS-driven melanocyte neoplasia progression. Exogenous fatty acid uptake was 
detected in melanoma tumor nodules by PET using the palmitic acid surrogate tracer 14(R,S)-18F-fluoro-6-
thia-heptadecanoic acid ([18F]-FTHA), consistent with upregulation of genes associated with fatty acid 
uptake found through microarray analysis. DESI-MS imaging revealed that FTHA uptake in tumors was 
heterogeneous. Transcriptome and lipidome analyses further highlighted dysregulation of 
glycerophospholipid pathways in melanoma tumour nodules, including increased abundance of phosphatidyl 
ethanolamine and phosphatidyl choline species, corroborated by DESI-MS which again revealed 
heterogeneous phospholipid composition in tumors. Overexpression of the gene encoding lipoprotein lipase 
(LPL), which was upregulated in zebrafish melanocyte tumor nodules and expressed in the majority of 
human melanomas, accelerated progression of oncogenic RAS-driven melanocyte neoplasia in zebrafish. 
Depletion or antagonism of LPL suppressed human melanoma cell growth; this required simultaneous fatty 
acid synthase (FASN) inhibition when FASN expression was also elevated. Collectively, our findings implicate 
fatty acid acquisition as a possible therapeutic target in melanoma, and the methods we developed for 
monitoring fatty acid uptake have potential for diagnosis, patient stratification, and monitoring 
pharmacological response. 
 
Significance: Findings demonstrate the translational potential of monitoring fatty acid uptake and identify 
lipoprotein lipase as a potential therapeutic target in melanoma. 
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Introduction 
 
Since Otto Warburg’s pioneering work, it has been recognised that cancer cells undergo metabolic changes 
to sustain their unbridled growth and dissemination. Lipids are major cell membrane components, signalling 
molecules, and also an energy source for cells. Altered lipid metabolism is essential for cancer progression, 
with lipids playing a key role in cancer cell proliferation and metastasis. Moreover, lipidomics is generating 
insight into disease mechanisms and identifying new therapeutic targets (1). While still sparse, emerging 
evidence implicates altered lipid metabolism in the development of melanoma too, with alterations in the 
lipidome differentiating benign skin neoplasms from melanoma (2). 
 
Fatty acids are building blocks for complex lipids incorporated into membranes as well as substrates for β-
oxidation, a major energy yielding reaction. How cancer cells obtain fatty acids is altered compared to 
healthy tissue, although the exact mechanisms remain to be elucidated. Fatty acids can be synthesized de 
novo by the enzyme fatty acid synthase (FASN). FASN is overexpressed in several cancers including 
melanoma (3, 4) and has been the target of drug development programs over decades (5). While FASN 
inhibitors can antagonise the proliferation of cancer cell lines including melanoma cell lines (6, 7), they have 
failed in the clinic due to insufficient efficacy and excessive toxicity (5). Fatty acids can also be scavenged 
from the blood supply, or potentially acquired through close contact with adipocytes (8, 9). Fatty acid 
scavenging by fatty acid binding protein 7 (FABP7) has been associated with enhanced proliferation and 
invasive capability of melanoma cells (10-12), while CD36-mediated fatty acid scavenging is prominent in 
metastasis-initiating melanoma cells (13). Further, it was recently shown that FATP1/SLC27A1, which 
transports long-chain fatty acids into cells, is enriched in melanoma compared to other cancer types (9), 
thereby highlighting the importance of fatty acid uptake for melanoma progression.  
 
The small domesticated fish, Xiphophorus, medaka and zebrafish, have been used for modelling melanoma 
since (in the case of Xiphophorus) the early decades of the last century. Melanocyte tumours arising in these 
models show comparable histopathology and molecular signatures to human melanoma due to the 
conservation of skin structures, melanocyte development, and signalling pathways controlling cell growth 
and invasion, all underpinned by the extensive conservation of vertebrate genomes (14). Previously, we have 
used transgenic zebrafish to establish a critical role for ERK MAPK in initiating melanocyte neoplasia and 
both PI3K and RAC in its malignant progression (15, 16). More recently, transgenic zebrafish were used to 
reveal cooperation between FATP1 and BRAFV600E in stimulating melanocyte neoplasia, while melanoma cell 
transplantation into zebrafish revealed preferential metastasis to adipose tissue (9). 
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Positron emission tomography (PET) is a highly sensitive in vivo imaging technique for visualising non-
invasively in 3D the distribution of an administered radiolabelled pharmaceutical (or tracer). 
Fluorodeoxyglucose-PET which detects glucose uptake capacity has become a well-established technique to 
visualise tumour locations. However, there have been relatively few PET-based studies investigating the role 
of lipid metabolism in cancer. PET tracers such as [11C]-choline and [11C]-acetate have emerged as useful 
tracers to study lipogenesis in tumours (17-20); but they cannot be used to investigate uptake of exogenous 
lipids. The tracer 14(R,S)-(18)F-fluoro-6-thia-heptadecanoic acid (herein [18F]-FTHA), an analogue of palmitic 
acid (a saturated fatty acid with a 16 carbon chain) has previously been used to study free fatty acid uptake 
in tissues (21) but has not yet been used to investigate fatty acid uptake in tumours.  
 
Tumours are not uniform, and this spatial heterogeneity complicates the study of metabolism. Tumour 
heterogeneity also poses a major problem for therapy, particularly when the disease progresses to the 
metastatic stage. PET is able to image metabolic heterogeneity in vivo somewhat, however it is limited by 
low spatial resolution— in the low millimetre range, but exact resolutions vary depending on the scanner 
model and radioisotope used— and its targeted nature (defined by the tracer used). In contrast to PET, 
desorption electrospray ionisation mass spectrometry (DESI-MS) imaging is an ambient ex vivo technique in 
which a stream of charged microdroplets is directed onto a tissue section in order to generate gaseous ions 
from species on the section surface. These ions are then taken up into a mass spectrometer inlet for analysis. 
Fatty acids and phospholipids ionise well by DESI-MS, making it an ideal lipid imaging tool (22). DESI-MS has 
the advantage of being an untargeted label-free technique, revealing the distribution of large numbers of 
lipids within a tissue section in one analysis at higher spatial resolution than achievable by PET (< 100 μm). 
Further, tandem mass spectrometry (DESI-MS/MS) can be performed post-imaging to identify individual lipid 
species.  
 
Here, transcriptome profiling and non-imaging mass-spectrometry based metabolomics have been 
combined with PET and DESI-MS imaging modalities to investigate fatty acid uptake and lipid metabolism in 
oncogenic RAS-driven zebrafish melanocyte neoplasia. Transcriptome profiling identified a gene expression 
program associated with disease progression, which included genes involved in fatty acid uptake and 
glycerophospholipid metabolism. Enhanced fatty acid uptake was confirmed by both PET and DESI-MS 
imaging of FTHA. DESI-MS and conventional mass spectrometry also confirmed enhanced 
glycerophospholipid metabolism. DESI-MS provided insight into tumour heterogeneity in lipid metabolism. 
The product of one disease progression associated gene, lipoprotein lipase (LPL), implicated in fatty acid 
scavenging (23), was found to be expressed in a majority of human melanoma cell lines and tumour samples. 
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LPL depletion or antagonism suppressed melanoma cell growth, although high concurrent FASN expression 
could compensate for reduced LPL activity. 
 
Materials and methods 
 
Zebrafish genetic models  
 
All regulated procedures involving zebrafish were ethically approved by The University of Manchester 
Animal Welfare and Ethical Review Body (AWERB) and carried out under licence in accordance with the UK 
Home Office Animals (Scientific Procedures) Act (1986), the guidelines of the Committee of the National 
Cancer Research Institute and the University's Policy on the Use of Animals in Research. Zebrafish were 
housed at the Biological Services Unit (BSU) at The University of Manchester at ~28 °C under a 14 hours 
light/10 hours dark cycle. Transgenic zebrafish expressing BRAFV600E or HRASG12V in the melanocyte lineage 
have been previously described (15). Generation of the NRASG12D construct was previously described (24) 
and breeding from founders resulted in the creation of a transgenic line. The HRASG12V or NRASG12D lines 
were crossed onto a mitfaw2/w2 (mitfa-/-) background to suppress melanocyte development and the NRASG12D 
transgene further onto a tp53M214K/M214K background to promote tumourigenesis. Melanocyte restoration and 
simultaneous overexpression of LPL, CCND1, mCherry or eGFP were then achieved by injection of embryos 
with a mitfa-minigene containing plasmid as previously described (25). Briefly, mCherry cDNA amplified from 
a vector and LPL cDNA amplified from zebrafish tumours using primers below were cloned into pDONR221 
using Gateway assembly (Gateway cloning kit, Thermo Scientific) to create pME mCherry and pME LPL. 
These were then incorporated into the mitfa-minigene containing destination vector together with p5′E 
mitfa promoter and p3′E-polyA by Gateway cloning. The p5′E mitfa promoter, and p3′E-polyA entry clones as 
well as the destination vector and CCND1 and eGFP control expression plasmids were kindly provided by Dr. 
Craig Ceol (UMass Medical School). Expression plasmid was injected into zebrafish zygotes along with Tol2 
mRNA. pCS2-TP plasmid for Tol2 mRNA generation was a kind gift from Dr. Koichi Kawakami (National 
Institute of Genetics). Only zebrafish embryos with near complete melanocyte rescue at 5 days post-
fertilisation (dpf) were retained and followed weekly for tumour development. Tumour nodules arising on 
fins, where the full mass could be evaluated, were measured in two directions using calipers (Expert Dual 
Reading Ip65 Digital Vernier Caliper 46611, Draper) when they were first detected and again two weeks later 
to determine growth rate. The cross-sectional area (A) was calculated using the formula π((d1+d2)/4)^2 and 
growth rate per week as (Aweek2-Aweek1)/2. Animals were sacrificed before clinical symptoms arose. 
 
Primers for mCherry and LPL amplification 
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mCherry  attB1F: GGGGACAAGTTTGTACAAAAAAGCAGGCTCGCCACCATGGTGAGCAAGGGCGAGGAGG 
attB2R: GGGGACCACTTTGTACAAGAAAGCTGGGTACCTTACTTGTACAGCTCGTCCATG 
LPL  attB1F: GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCACCATGATGTTTAATAAGGGGAGAG 
attB2R: GGGGACCACTTTGTACAAGAAAGCTGGGTACTTTACTCGTTGTTCTGTTTG 
 
Transcriptome Analysis 
 
The microarray slides, custom-designed by Agilent Technologies, have been described elsewhere (26) and 
the design submitted to the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo) with 
accession number GPL7735. For RNA isolation, three pools of 10 caudal fins or three pools of 6 tumours 
within caudal fins were snap-frozen in liquid nitrogen and subsequently stored at -80 °C. Samples were 
homogenized in 1 ml of TRIzol reagent (Thermo Fisher Scientific), and subsequently total RNA was extracted 
according to the manufacturer's instructions. RNA samples were incubated for 20 minutes at 37 °C with 10 U 
of DNase I (Roche Applied Science) to remove residual genomic DNA before purification using the RNeasy 
MinElute Cleanup kit (Qiagen). The integrity of the RNA was confirmed by lab-on-chip analysis using the 2100 
Bioanalyzer (Agilent Technologies). Samples used for microarray analysis had an average RNA integrity 
number value of 9 and a minimum RNA integrity number value of 8. 
 
RNA labelling was performed as described elsewhere (26). For comparison, aRNA of wild-type fish were 
coupled with Cy3 and aRNA of transgenic lines were coupled with Cy5. Hybridization and scanning were 
performed according to standard Agilent protocols. The feature extraction software version 9.5, protocol 
ge2_V5_95 from Agilent was used to generate the feature extraction data. For the background subtraction 
the option 'No background subtraction and spatial detrend' was used. The arrays were scanned twice with 
10% PMT and 100% PMT laser power and the XDR function was used to extend the dynamic range by 10-
fold. Microarray data was imported into Rosetta Resolver 7.0 (Rosetta Biosoftware) and subjected to default 
ratio error modelling. Data analysis was performed for unigene clusters (Unigene Build 105) and significance 
cut-offs for the ratios of wild-type vs. a particular transgenic line were set at 2-fold change and p ≤ 10-5. The 
two-dimensional hierarchical cluster analysis was performed with Rosetta Resolver settings for 
agglomerative algorithm (average link) with cosine correlation. The microarray data discussed in this 
publication have been deposited in GEO with Series accession number GSE76791 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76791).  
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Human orthologs of the differentially expressed genes were determined using BioDBnet (27) and BioMart 
(28). Gene Ontology (GO) enrichment analysis for the human orthologs was performed using PANTHER 
Overrepresentation Test (Fisher’s Exact test, Bonferroni correction for multiple testing) through the Gene 
Ontology Consortium enrichment analysis platform (29). For the GO analysis, gene function and gene 
ontology terms were based on the PANTHER Classification System (GO Ontology database Released 2018-11-
15) (doi: 10.1038/nprot.2013.092).  
 
[18F]-FTHA PET scanning 
 
Production of [18F]-FTHA was carried out via nucleophilic [18F] fluorination of a benzyl-14-(R,S)-tosyloxy-6-
thiaheptadecanonate precursor (ABX advanced biochemical compounds), based on the method by DeGrado 
et al. (30) and was fully automated on a TRACERlab FXFN radiochemistry system (GE Healthcare). Animals 
were not fed the evening prior to scanning (to limit background signal in the gut). Fish were immersed in 
200ml of water containing 100 MBq of [18F] FTHA for 2 hours. Animals were then anaesthetised with MS222 
and placed in cuvettes (held in place with sponge) and cuvettes placed in falcon tubes filled with ice water. 
Static PET scans were then performed for 5 and 10 minutes on a pre-clinical PET scanner (Inveon, Siemens, 
Germany). Fish were culled immediately after scanning without recovery from anaesthetic, and flash-frozen 
in isopentane. PET images were reconstructed using the 3d-OSEM/MAP algorithm (4 OSEM3D iterations and 
no MAP iterations, with a resolution of 1mm). Images were visualised using Inveon Research Workplace 
software (Siemens, Germany). Regions of interest (ROIs) were drawn manually over tumours and the 
SUVmean (an average of all voxels) was calculated. Normalisation was performed using the dose of [
18F]-FTHA 
(average dose was 4 MBq) and the weight of the fish (average weight was 0.5g) to give standardised uptake 
values.  
 
DESI-MS imaging  
 
Fish were immersed in 100 ml of water containing 0.5 mg of FTHA for 30 mins, culled, then flash frozen in 
isopentane. Fish were sectioned to 12 µm onto glass slides. Imaging experiments were carried out on a 2D 
DESI system (Prosolia, Indianapolis, USA) mounted on a Xevo-G2-XS quadrupole-time of flight (Q-TOF) 
(Waters Corporation, Wilmslow, UK). The solvent spray consisted of 95% methanol and 5% water. Spray 
conditions used were a flow rate of 2 µl/minutes (using a syringe pump from Harvard Apparatus, Inc., 
Holliston, MA), with a nebulising gas of nitrogen at 4 bar pressure. Typical positions of the sprayer were used 
(sprayer 1.5mm above surface, 6mm sprayer to capillary distance, 75˚ sprayer impact angle, 5˚ collection 
capillary angle). The source temperature was 100 ˚C and the capillary voltage was set between 4.82 and 5kV. 
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Images were acquired using a scan rate of 1-10 scans/second, and a mass range of 50-1200 Da. The spatial 
resolution varied from 40-200 μm. Images were processed and normalised to total ion current (TIC) using the 
High Definition Imaging (HDI) v1.4 (Waters, Wilmslow, UK). MS/MS experiments were carried out on a Xevo-
G2-XS Q-TOF mass spectrometer using argon as the collision gas and a collision energy range of 20 V - 40 V. 
Spray conditions were the same as DESI imaging. Interpretation of spectra was carried out with the help of 
LIPID MAPS Lipidomics Gateway database (http://www.lipidmaps.org) (31). 
 
Haematoxylin and eosin staining 
 
Haematoxylin and eosin (H&E) staining was carried out on sections after DESI-MS imaging, and also on 
adjacent sections. Slides were immersed in xylene (Sigma-Aldrich, UK) for two minutes, and then transferred 
to industrial methylated spirit (Sigma-Aldrich, UK) for 4 x 2 minutes. Sections were then immersed in tap 
water followed by 3 minutes in Harris haematoxylin (Sigma-Aldrich, UK), a rinse in hot water, and a one 
second dip in eosin (Leica, UK). Slides were transferred to industrial methylated spirit for (4 x 2 minutes), 
then to xylene (4 x 2 minutes), and left to dry. Aqueous mounting media (Abcam, UK) was used to mount 
coverslips (VWR, UK) onto slides and left overnight to dry.  Images were acquired using a [20x/0.80 Plan Apo] 
objective using the 3D Histech Pannoramic 250 Flash II slide scanner, and processed using Panoramic viewer 
(3D HISTECH, Hungary).  
 
Nile Red staining 
 
Nile Red (Sigma-Aldrich, UK) stock solution was prepared at 0.5 μg/mL in acetone. For staining the stock was 
diluted 1:1000 in 80% glycerol. Cryosections were allowed to defrost for 40 minutes at room temperature. 
Samples were briefly washed with distilled water before 100 μL of Nile Red was added to each slide. Samples 
were incubated for 5 minutes in the dark before being cover-slipped and immediately imaged. Images were 
acquired on an Olympus BX51 upright microscope using a 10x/ 0.30 Plan Fln objective using a Coolsnap ES 
camera (Photometrics) through MetaVue Software (Molecular Devices). Specific band pass filter sets for FITC 
and Texas Red were used to prevent bleed-through from one channel to the next. Images were then 
processed and analysed using ImageJ (http://rsb.info.nih.gov/ij). 
 
Lipid extraction and mass spectrometry analysis of metabolic pathways 
 
Wild-type and V12RAS fish skin and tumour nodules from V12RAS fish were pooled to a mass between 25–
35 mg. At least 6 biological pools were gathered for each sample. Extraction of tissue metabolites was 
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performed as previously described by lysing tissue in a mixture of chloroform, methanol and water to 
separate polar (methanol/water phase) and non-polar (chloroform phase) metabolites. Non-polar fractions 
were dried under vacuum for 16 hours. Ultra-high performance liquid chromatography mass spectrometry 
(UHPLC-MS) analysis of the non-polar extracts was performed using an (Accela UHPLC system coupled to an 
Orbitrap Velos MS. Univariate statistical tests (mean ratio with confidence intervals, Mann-Whitney U-test) 
and multivariate principal component analysis (PCA) were applied in R. Metabolites were annotated applying 
the software PUTMEDID_LCMS (32); all metabolites were annotated to level 2 as defined in the reporting 
standards for chemical analysis constructed by the Metabolomics Standards Initiative (33).  
 
Integrating Transcriptomic and Lipidomic Analyses with MetScape 
 
The MetScape (34) plugin for Cytoscape was used for integration. The analysed transcriptome data and mass 
spectrometry data were entered with their respective fold-change and P-values. The gene data was added 
with the human homologue Entrez gene identifier; the metabolites were added with KEGG compound 
identifiers. All mapping was performed with unmodified, standard settings and MetScape workflow. 
 
Cell culture and LPL depletion by siRNA 
 
All human melanoma cell lines were maintained in DMEM with L-glutamine, pyruvate and sodium 
bicarbonate (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Life Technologies) and 1% 
penicillin/streptomycin solution (Sigma-Aldrich). Cell lines were authenticated using STR analysis. Normal 
human melanocyte (NHM) cells (Life Technologies) were maintained in medium 254 (Life Technologies) 
supplemented with 1% human melanocyte growth supplement (HMGS) (Life Technologies). All cells were 
maintained under standard conditions at 37°C with 5% CO2 and routinely screened for mycoplasma 
infection. 
 
For LPL depletion, siRNA was purchased from Dharmacon (sequences below). All siRNAs were diluted to 20 
µM in 5X siRNA resuspension buffer (GE Dharmacon). The cells were plated 24 hours prior to transfection in 
6 well plates and at a cell number to allow the cells to be at 60% confluence (200,000 cells per well).  Cells 
were transfected with 20 pmol of siRNA using the Lipofectamine RNAiMAX transfection reagent (Thermo 
Fisher Scientific) as instructed by the manufacturer. A non-targeting control was included in every 
experiment. Fresh media was added after 24 hours or cells were collected. 
 
siRNA sequences 
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control siRNA AAUAUAAUCACUAUCAGGUGC 
LPL siRNA A GGCCUCUGCUUGAGUUGUA 
LPL siRNA B CCUACAAAGUCUUCCAUUA 
 
Drug Dose-Response Analysis and Survival Assays 
 
For drug dose-responses assays, cells were plated in 96-well plates and treated with serial dilutions of 
GSK264220A (Tocris) and C75 (Sigma Aldrich) for 72h. Cell survival was quantified by fixing and staining cells 
with 0.5% crystal violet in 4% formaldehyde and then measuring the absorbance of the solubilized dye (in 2% 
SDS in PBS) at an optical density of 595nm.  
 
RNA isolation and real-time qPCR analysis 
 
RNA was isolated from cells using TRIzol (QIAGEN). cDNA was synthesized from RNA using the Omniscript 
reverse transcriptase kit (QIAGEN) according to the manufacturer’s instructions. Amplification of specific PCR 
products was detected using an Agilent technologies Stratagene Mx3000P system, the SensiMix SYBR No-
ROX Kit (Bioline) and the following cycling conditions: 95°C for 10 minutes and 40 cycles of 95°C for 30s, 55°C 
for 45s and 72°C for 45s. Primer efficiency was previously determined > 90% and < 110% and correlation (R2) 
over three log concentrations > 0.97. Relative expression using beta-actin (ACTB) expression to normalise 
and normal human melanocytes as a common reference was calculated using the ΔΔCt approach. 
 
Primers used for qPCR analysis:  
LPL F: GACACAGCTGAGGACACTTG 
R: TGGAGTCTGGTTCTCTCTTG 
FASN F: CTTCCGAGATTCCATCCTACGC 
R: TGGCAGTCAGGCTCACAAACG  
CD36 F: GACCTGCTTATCCAGAAGAC 
R: TTGCTGCTGTTCATCATAC 
FABP7 F: AGCTGACCAACAGTCAGAAC 
R: ATGTGCTGAGAGTCCTGATG 
FATP1 F: AGTACAACTGCACGATCGTC 
R: GCAGTCATAGAGCACGTCAG 
FATP2 F: AGTTGGTGCTGTTGGAAGAG 
R: ACCAGAAGTCCAACTTCACC 
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ACTB F: GCAAGCAGGAGTATGACGAG 
R: CAAATAAAGCCATGCCAATC 
 
LPL Immunofluorescence 
 
Cells were plated onto UV-treated cover slips contained in 6 well plates, washed with 1x PBS and then placed 
in a 4% paraformaldehyde and 1X PBS solution for 30 minutes. Coverslips were then washed in 1x PBS and 
again in 1M glycine (Sigma Aldrich). Coverslips were then incubated in 0.1% TX100/PBS (Sigma Aldrich) 
solution for 4 minutes to permeabilise cells before being incubated with a 1:100 dilution of mouse A4 anti-
LPL monoclonal (ab21356, Abcam) in 0.5 µg/mL BSA/TBST for 20 minutes. Following this, coverslips were 
washed three times in PBS and then incubated with a secondary antibody conjugated to CY3 for a further 20 
minutes. Coverslips were then washed in PBS and incubated with Cy3-labelled secondary antibody for 2 hr at 
RT and mounted using DAPi containing vectashield. (Vectorshield Antifade with DAPI, Vector Laboratories). 
Slides were sealed with clear polish. Images were collected on a Olympus BX51 upright microscope using a 
10x/ 0.30 Plan Fln objective and captured using a Coolsnap ES camera (Photometrics) through MetaVue 
Software (Molecular Devices). Specific band pass filter sets for DAPI and Cy3 were used. Images were then 
processed and analysed using ImageJ (http://rsb.info.nih.gov/ij). 
 
Western blotting  
Laemmli buffer was added to cells for 1 minute before the well was scraped with a cell scraper and the 
buffer was transferred to a 0.5 mL tube and sonicated (VibraCell X130PB, Sonics Materials) for 30 seconds at 
20% amplitude. Samples were then boiled for 5 minutes before being loaded onto precast gels in the 
SureLock© Precast Gel System (Novex). Protein was the transferred to nitrocellulose membrane and blocked 
with 5% BSA in TBST or 5% Skimmed Milk in TBST dependent on the antibody (see table below). Primary 
antibodies were incubated at 4 °C overnight, blots were washed in TBST and secondary antibody was added 
at 1:5000 for 1 hour at room temperature. The blots were then washed again before application of Western 
Lightning© Plus ECL chemiluminescence for 1 minute. The blot was then exposed to X-ray film (Biomax MR 
Film, Kodak) developed using a JP-33 Film Processor (JPI Healthcare) and subsequently scanned on an HP 
flat-bed scanner. 
 
Antibodies used in western blotting. 
Antibody Concentration 
Goat α h/m polyclonal LPL (R&D Systems) 1:1000 (5% BSA/TBST) 
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Mouse α CD36 (FA6-152) (Abcam) 1:2000 (5% BSA/TBST) 
Rabbit α FASN (C20G5) (Cell Signalling) 1:1000 (5% BSA/TBST) 
Rabbit α ERK2 (Santa Cruz) 1:2000 (5% Milk/TBST) 
Rabbit α β-Tubulin (Santa Cruz) 1:2000 (5% Milk/TBST) 
HRP conjugated Donkey α Goat Secondary (Santa Cruz) 1:5000 (5% Milk/TBST) 
HRP conjugated Donkey α Rabbit Secondary (GE Healthcare) 1:5000 (Mirrors Primary) 
HRP conjugated Sheep α Mouse Secondary (GE Healthcare) 1:5000 (Mirrors Primary) 
 
Immunohistochemistry for LPL 
 
4m sections obtained from formalin-fixed, paraffin-embedded archive samples, were stained by 
immunochemistry. Briefly, after deparaffinisation, antigen retrieval was performed by heating the slides 
placed in a TRIS-Buffer pH 9 using a pressure cooker. A mouse monoclonal antibody A4 against human LPL 
(ab21356, Abcam) diluted 1:300 was then applied for 120 minutes at room temperature. Secondary staining 
was performed using the Dako REAL detection System, Alkaline Phosphatase/RED, Rabbit/Mouse kit, based 
on the labelled streptavidin-biotin method. The diagnosis as well as the intensity of staining and the 
proportion of positive tumor cells were ascertained for each sample by a clinical dermatopathologist (JK). 
 
Results 
 
Transcriptome analysis reveals deregulated lipid metabolic pathways in advanced melanocyte neoplasia 
 
Previously, we generated transgenic zebrafish displaying different grades of melanocyte neoplasia. 
Transgenic animals expressing BRAFV600E alone develop benign melanocyte hyperplasia, manifested as 
broader and darker stripes, while expression of HRASG12V alone results in malignant melanocyte neoplasia 
that initially expands horizontally in the epidermis and hypodermis enveloping the entire body other than 
the ventral surface (the radial growth phase or RGP), and then vertically, infiltrating the subcutaneous tissue 
(the vertical growth phase or VGP) and resulting in mainly raised tumour nodules (Fig. 1A) (15). To minimize 
contamination from mRNA arising from non-diseased tissue that could add noise and drown out signal, 
transcriptome profiling was performed on RNA extracted from caudal fins of wild-type, BRAFV600E or HRASG12V 
transgenic animals or tumour nodules located within caudal fins of HRASG12V transgenic animals, using a 
customised Agilent 44K zebrafish transcriptome microarray (26). 
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Considering only genes with highly significant (P<0.0001) differential expression to minimise false positives 
and a fold-change of at least 2 compared to wild-type (Supp. Table 1), the VGP tumour model had the 
greatest number of differentially expressed genes (DEGs) totalling 4,429 (Fig. 1B). Hierarchical clustering of 
DEGs suggested a closer relationship between RGP and VGP profiles than any other two-way comparison 
(Fig. 1C). Indeed, a sizeable proportion of DEGs were shared in common between RGP and VGP 
demonstrating potentially step-wise progression, but much less so between BRAF and RAS models reflecting 
their very different progression pathways (Fig. 1D). Several groups have shown that melanoma develops 
independently from benign neoplasia and this extends to gene expression programs (35). Further, 
melanocytes expressing BRAFV600E alone have likely undergone a course of proliferation and senescence (25) 
that would mean samples are divergent both from wild type skin as well as from the V12RAS model. Many 
unique DEGs were detected in V12RAS-driven VGP melanocyte neoplasia. This is to be expected as 
melanomas increase their genetic diversity as they progress, while hypoxia in larger lesions also generates 
significant changes in gene transcription (36). 
 
DEGs were converted to human orthologues using BioBDnet and BioMart, which were then subjected to 
Gene Ontology (GO) enrichment analysis for biological processes. GO enrichment analysis of the VGP up-
regulated genes highlighted metabolism as an altered process, relating to 19% of up-regulated genes of 
which lipid metabolism genes constituted 28% (Fig. 1E; see also Supp. Table 2 for a list of genes comprising 
this ontology that are also exclusive to the VGP samples). Over-represented GO terms associated with RGP 
up-regulated genes included cell communication, signal transduction, developmental process and MAPK 
signalling cascade, while development and signal transduction related GO terms were enriched for BRAF up-
regulated genes. In contrast to VGP, lipid metabolism GO terms were not significantly over-represented in 
up-regulated genes in RGP or VBRAF models (Supp Fig. 1).  
 
Melanocyte tumours scavenge exogenous free fatty acids  
 
Two gene products, LPL and FABP7, encoded by the VGP DEGs lpl (up-regulated 9.5-fold exclusively in VGP) 
and fabp7a (up-regulated 24.5-fold), are implicated in fatty acid scavenging in cancer (23). We also detected 
40.5-fold up-regulation of the fatty acid transporter FATP2/SLC27A2 in VGP samples, which encodes a long-
chain fatty acid transporter highly related to FATP1/SLC27A1, recently described as being enriched in 
melanoma compared to other cancer types and linked to melanoma development (9). LPL secreted by cells 
into the interstitial space and presented on the vasculature glycocalyx hydrolyses dietary triglycerides 
transported as chylomicrons or very low density lipoprotein to release free fatty acids, which can then be 
transported across the plasma membrane by fatty acid transporters such as CD36, FABP7, FATP1 and FATP2. 
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LPL and FABP7 are overexpressed in several cancers (23, 37). Increased expression of FABP7 has been 
observed in human melanoma, and expression correlates with aggressive tumours and poor prognosis (10-
12). These findings suggest melanoma tumours increase their fatty acid scavenging in order to deal with an 
increased demand for fatty acids. 
 
In order to image free fatty acid uptake by tissues in vivo, we employed [18F]-FTHA, a radiolabelled palmitic 
acid analogue, as a PET tracer (21). A PET imaging protocol was developed for zebrafish (see methods) that 
did not require modification to the PET scanner. PET scans of wild-type fish 2 hours post administration 
revealed [18F]-FTHA accumulation predominantly in the anterior abdomen (Fig. 2A). However, due to the 
limited spatial resolution, it was difficult from the PET scans alone to specify where [18F]-FTHA had been 
taken up. Therefore, DESI-MS imaging was carried out after PET scans, in order to utilise its high spatial 
resolution to determine a more precise location for the tracer. The concentration of FTHA used for PET (~8 
nmol/L) was, however, below the limit of detection of DESI-MS. Therefore, unlabelled FTHA was added at a 
higher concentration. DESI-MS imaging of wild-type fish with higher FTHA dosing (8 μmol/L) revealed that 
FTHA accumulated mainly in the liver (Fig. 2B), where dietary fatty acids are converted into triglycerides for 
incorporation into lipoproteins for distribution around the body. DESI-MS/MS was then carried out on 
sections in order to confirm that the negative ion mode peak at m/z 305.30 was indeed FTHA, and not an 
endogenous species. This yielded a diagnostic ion with m/z 205.18 (Supp Fig. 2). Previous studies have 
shown that although FTHA will predominantly enter the β-oxidation pathway, it can also be incorporated 
into phospholipids via lipogenesis with the pathway it is used by being tissue dependent (38). DESI-MS/MS 
was performed for lipid peaks co-localising with FTHA in the liver. One of these peaks (m/z 861) yielded small 
amounts of FTHA that had been incorporated into this lipid after 30 mins exposure (Supp Fig. 3). However, 
identification of m/z 861 was not possible, as spectra were indicative of more than one unresolved lipid at 
m/z 861. Nevertheless, this finding indicates that FTHA can enter the lipogenesis pathway, at least in liver 
cells. 
 
Next, PET scans of V12RAS transgenic zebrafish bearing tumour nodules revealed concentration of [18F]-
FTHA in 8/8 tumours (Fig. 2C and D), consistent with fatty acid uptake being elevated in V12RAS-transformed 
melanocytes as predicted from transcriptomics. Previously it was shown that enhanced fatty acid uptake 
through increased expression of FATP1 in zebrafish melanoma cells resulted in increased fatty acid storage 
as lipid droplets, while FATP1 expression was shown to correlate with lipid droplets in patient melanoma 
biopsies (9). Using Nile Red staining we detected abundant lipid droplets in V12RAS-driven melanoma 
nodules, again consistent with increased fatty acid uptake (Supp Fig. 4A,B). As in wild-type animals, FTHA 
was not detected by DESI-MS in the tumour-bearing fish using the concentrations used in PET. Therefore, 
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fish were treated with a higher concentration of unlabelled FTHA (8 μmol/L) prior to DESI-MS imaging. In the 
representative example shown, FTHA localised in both snout and tail tumours as well as in the liver (Fig. 2E-
H). Whereas uptake of FTHA was homogenous in the snout tumour, uptake was heterogeneous in the fin 
tumour (a finding that would not be apparent by PET scans alone) and did not co-localise with areas of the 
most densely packed cells, as may have been expected. Both PET and DESI-MS indicated that FTHA 
accumulation was markedly higher in tumour nodules than flat areas of skin containing only RGP melanoma, 
consistent with our transcriptomic analysis identifying up-regulation of fatty acid scavenging genes 
selectively in VGP melanoma.  
 
Glycerophospholipid metabolism is deregulated in malignant melanocyte neoplasia  
 
UHPLC-MS metabolomics was performed on non-aqueous solvent extracts of wild-type skin, skin containing 
RGP melanoma, and on VGP tumour nodules excised from the body wall to determine changes in metabolite 
concentration during melanocyte neoplasia progression. A number of species from all lipid metabolite 
classes changed in abundance compared to wild-type skin, increasing with disease progression and mirroring 
the diversity seen in the transcriptome (see Supp. Table 3 and Supp Fig. 5A,B). PCA of metabolites detected 
by UHPLC-MS indicated a clear separation between wild-type, RGP and VGP samples with a more significant 
separation observed for negative ion mode data (Fig. 3A). The transcriptome and metabolome data were 
integrated using MetScape, which highlighted the glycerophospholipid metabolism pathway in both the VGP 
(Fig. 3B) and RGP (Supp. Fig. 5C) samples. Major components of the cell membrane include phosphatidyl 
choline (PC) and phosphatidyl ethanolamine (PE) species, which increased in relative abundance in zebrafish 
V12RAS-driven melanocyte neoplasia, beginning in the RGP model and becoming more prominent in the 
VGP model. This change was also accompanied by a depletion of phosphatidylserine (PS), potentially driven 
by increased expression of phosphatidylserine decarboxylase (PISD), as revealed by the transcriptome 
analysis (up-regulated 3.7-fold exclusively in VGP), which catalyzes the formation of PE by decarboxylation of 
PS. DESI-MS was carried out to visualise phospholipid species in VGP melanoma tumours. As well as 
revealing clear differences in glycerophospholipid abundance between the tumour and healthy tissue, 
imaging revealed heterogeneity of glycerophospholipid species, including PE species in the tumour (Fig. 3 
C,D and Supp Fig. 6A,B). 
 
LPL is a potential therapeutic target especially when de novo fatty acid synthesis is not enhanced by FASN up-
regulation 
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To evaluate the potential for fatty acid scavenging in human melanoma, we quantified expression of LPL, 
CD36, FABP7, FATP1 and FATP2 mRNA by reverse-transcription coupled real-time PCR (RT-PCR) in a panel of 
established human melanoma cell lines (Supp. Table 4) and contrasted this to levels in normal human 
melanocytes (NHM). This revealed elevated LPL transcript in all the melanoma cell lines, both NRAS and 
BRAF mutant, across a wide range of fold-changes compared to NHM (Fig 4A). Elevation of LPL mRNA 
reached more than 40-fold, whereas fewer instances of significant mRNA upregulation for the fatty acid 
transporters were observed, and fold-change was only ever modest (less than 5-fold). Western blotting for 
LPL on protein lysates extracted from melanoma cell lines in this panel revealed elevated protein compared 
to melanocytes consistent with the extent of mRNA upregulation (Supp. Fig. 7A), increased LPL expression 
was also confirmed by immunofluorescence staining for LPL (Supp. Fig. 7B). Moreover, positive 
immunohistochemistry staining revealed LPL expression in 90% or more of primary and metastatic 
melanoma tumours (Fig. 4B). LPL was also detected in 77% of naevi, but was largely restricted to nests of 
naevocytes occupying the junction between the epidermis and the dermis (Fig. 4C). LPL staining appeared 
specific, as outside the tumour a positive signal was detected, as expected (39), only in adipocytes and 
capillary lumens (Supp. Fig. 7C). There were significantly more examples of strong LPL staining (++ and +++) 
in melanoma cases (primary and metastatic) compared to naevi (p = 0.005, χ2 test).  
 
By investigating mRNA expression for LPL and the fatty acid transporters listed above in cutaneous 
melanoma cases collected and analysed by the Cancer Genome Atlas network (40), we found no significant 
effect from NRAS and BRAF mutation status (Supp. Fig. 8A). LPL mRNA expression was most highly correlated 
with CD36 mRNA followed by FABP7 mRNA, and there was no correlation between LPL expression and either 
FATP1 or FATP2 mRNA expression (Supp. Fig. 8B). Further, although fatty acid scavenging was shown to 
enhance metastasis of melanoma cells (13), mRNA for LPL and the fatty acid transporters listed above was 
not more abundant in metastatic samples in the TCGA collection than primary lesions (Supp. Fig. 8C), and 
there was no difference evident in LPL expression in metastases vs primary from immunohistochemistry (Fig. 
4B; p = 0.91, χ2 test).  Therefore enhanced fatty acid scavenging is most likely a common feature of both 
primary and secondary tumours.  
 
Upregulation of LPL mRNA was only detected in VGP zebrafish melanocyte neoplasia (not in RGP or benign 
neoplasia models). To determine whether in this V12RAS driven-model upregulation of LPL is sufficient to 
enhance progression from RGP to VGP, we turned to a transient transgenesis assay originally devised to 
detect co-operation between oncogenic BRAF and other candidate melanoma oncogenes (25). The V12RAS 
transgene was crossed into a mitfa mutant background to suppress melanocyte development. One-cell stage 
eggs from these animals were then injected with a plasmid containing a wild-type mitfa minigene to rescue 
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melanocyte development while expressing a second mitfa-promoter driven cassette encoding either 
mCherry (as a negative control), LPL or CCND1 (a positive control) (Supp. Fig. 9A,B). Tumour nodule 
formation was then followed in animals where pigmentation had been nearly completely restored while 
embryos. All pigment-rescued animals developed the characteristic RGP appearance of the parent V12RAS 
line (Fig. 5A). Compared to mCherry, however, co-expression of LPL accelerated tumour nodule formation 
comparable to CCND1 (Fig. 5B). Moreover, co-expression of LPL increased tumour growth rate compared to 
either mCherry or CCND1 (Fig. 5C). Using the same transient transgenesis approach, a weaker but still 
significant cooperation was also observed with NRASG12D (Supp. Fig. 9C,D). 
 
Turning to human melanoma cells, knockdown of LPL using two independent siRNA oligonucleotides 
reduced cell growth by as much as 70% in WM852 cells and 50% in WM266-4 cells, but did not affect A375 
cells (Fig. 5D). To address the difference in sensitivity to suppressing LPL in melanoma cells we evaluated 
expression of FASN required for de novo fatty acid synthesis by reverse transcription coupled RT-PCR and 
western blotting. FASN mRNA and protein levels were significantly higher in A375 cells and WM266-4 cells 
relative to primary melanocytes but also compared to WM852 cells (Fig. 5E and Supp Fig. 9E), implying de 
novo fatty acid synthesis may complement fatty acid scavenging in A375 and WM266-4 cells but not WM852 
cells. WM852 cells were also more sensitive to a small molecule inhibitor of LPL (GSK264220A) (41) than 
either A375 cells or WM266-4 cells (Fig. 5F). Significantly, combined treatment with FASN inhibitor C75 (42) 
and LPL inhibitor synergized to suppress the growth of A375 cells and WM266-4 cells but not WM852 cells 
(Fig. 5F). Moreover, FASN expression is relatively low in WM1361 cells and high in WM35 cells (Fig. 5E and 
Supp Fig. 9E) and consistent with predictions from above WM1361 cells were sensitive to LPL inhibitor with 
no added effect of FASN inhibitor, while WM35 were less sensitive to LPL inhibitor but could be sensitized by 
addition of FASN inhibitor (Fig. 5F).  
 
Discussion 
 
Fatty acids are used by cells for both energy production (β-oxidation) and lipogenesis to form membrane 
phospholipids. As cancer cells have higher energy demands and proliferate at higher rates than healthy cells, 
increased acquisition of fatty acids can be expected. However, tumours can acquire fatty acids by different 
mechanisms: uptake from outside the cell or de novo synthesis (5). VGP up-regulated DEGs included lpl, 
fabp7a, and fatp2/slc27a2, whose gene products are implicated in the uptake of exogenous fatty acid. 
Kamphorst et al. have shown that oncogenic RAS-driven tumours source fatty acids by scavenging them as 
lysophospholipids (43), demonstrating also that RAS-driven tumours are dependent on fatty acid scavenging. 
It has also recently been reported that the up-regulation of the scavenger fatty acid receptor, CD36, is 
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correlated to metastases and poor prognosis in melanoma and is a marker of tumour initiating cells (13). Of 
interest, culturing melanoma cells with adipocytes stimulates melanoma cell proliferation and this affect 
could be reproduced with palmitate alone. Further, the transfer of fatty acid from adipocytes to melanoma 
cells could be directly visualised (8). Indeed, proximity to adipose has been demonstrated to facilitate the 
development of zebrafish melanocyte neoplasia through the supply of exogenous fatty acid and this could 
be inhibited using a FATP inhibitor (9). It is notable that relative to normal skin we observed reduced 
triglyceride levels in both RGP and VGP V12RAS-driven melanocyte neoplasia, in keeping with depletion of 
adipose lipid reserves. 
 
Tumour cells can also synthesise fatty acids de novo, and FASN and SCD-1 are crucial enzymes in this 
pathway. FASN synthesises palmitate from acetyl-CoA and malonyl-CoA, and palmitate can undergo 
subsequent changes such as elongation and desaturation. SCD-1 generates unsaturated fatty acids such as 
oleic acid (18:1) and palmitoleic acid (16:1), by inserting a double bond into a saturated fatty acid at the Δ9 
position. FASN and SCD-1 have been found to be overexpressed in many cancers including melanoma (3, 4, 
44), implying that de novo fatty acid production is also increased. Scda (6.5-fold) and -b (4.1-fold) 
overexpression but not fasn overexpression was also observed in zebrafish V12RAS-driven VGP melanocyte 
neoplasia. Since SCD1 could just as well desaturate fatty acids that are scavenged as synthesized de novo, its 
upregulation here does not necessarily indicate increased de novo synthesis. Cells can also break down 
phospholipids to generate free fatty acids. Expression of several PLA2 isoforms (pla2g6, pla2g7 and pla2g10) 
appeared to be up-regulated (2.0-5.3 fold) in zebrafish V12RAS-driven VGP melanocyte neoplasia. PLA2 
enzymes are a diverse family of phospholipases which hydrolyse phospholipids to generate free fatty acids 
(commonly arachidonic acid) and lysophospholipids. Lysophospholipids and arachidonic acid are both 
signalling molecules, with arachidonic acid being a precursor of several bioactive eicosanoids, which in turn 
are involved in inflammatory mechanisms. PLA2 deregulation in cancer is increasingly recognised (45) with 
the PLA2G6 gene being associated with heightened risk of malignancy developing in naevi (46, 47), and the 
PLA2 family being investigated as a source of potential drug targets (45). 
 
PET and DESI-MS imaging using the palmitic acid analogue FTHA were used as complementary imaging 
modalities to reveal enhanced fatty acid scavenging in zebrafish melanocyte neoplasia, implied by the 
transcriptomic data. Melanocyte tumours may be scavenging palmitate (and hence FTHA) to be used in β-
oxidation or in lipogenesis. β-oxidation provides an alternative energy source to glucose and has been linked 
with the metastatic phenotype of melanoma cell lines (48). Lipogenesis rates will also be increased in cancer, 
and so it is plausible that FTHA may also be incorporated into more complex lipids. Indeed, a previous study 
found that exogenous palmitate was incorporated into glycerophospholipids, sphingolipids, and ether lipids 
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in a range of human cancer cells (49). However, no lipids were found that co-localised exactly with the FTHA 
distribution in tumours, making targeted MS/MS experiments difficult. It is possible that administering the 
FTHA for a longer period of time would give rise to more lipids containing FTHA as a fatty acid chain. 
 
In order to understand changes to lipid metabolism more precisely, transcriptome data were integrated with 
UHPLC-MS metabolome data. This integrated approach, further corroborated by DESI-MS imaging, 
highlighted the glycerophospholipid metabolism pathway, which is critical to the synthesis of plasma 
membrane phospholipids, playing a role in melanocyte neoplasia progression. Aberrant glycerophospholipid 
metabolism has previously been implicated in melanoma metastatic potential (50). Phospholipids, including 
PC and PE species, were up-regulated in VGP tumours compared to the surrounding healthy tissue, while PS 
species were down-regulated. Of note, the mitochondrial protease Lactamase Beta (LACTB) has been shown 
to exert its tumour suppressor function through regulating the stability of PISD, which we observed to be up-
regulated in zebrafish V12RAS-driven melanocyte VGP neoplasia. Loss of LACTB expression in oncogene-
expressing breast epithelial cells resulted in elevation of PISD protein accompanied by a conversion of 
mitochondrial PS to PE and lysoPE that was necessary for cancer cell proliferation and dedifferentiation (51). 
Additionally, lipidomics comparing lipid species in human and zebrafish BRAF mutant melanoma cells co-
cultured with adipocytes to those cultured alone, or those recovered from tumors in vivo contrasted to 
those cultured in vitro also revealed increased PC and PE species (9), indicating that our V12RAS-driven 
zebrafish melanocyte malignancies resemble oncogenic BRAF-driven malignant melanocytes stimulated by 
adipocytes. Choline containing biomolecules are increased in human primary and metastatic melanoma 
when measured by magnetic resonance imaging (52, 53) as in other cancers such as prostate cancer (54). 
Indeed, altered anabolism but also catabolism of PC (to produce important signalling molecules such as 
diacylglyceride) are now considered a pervasive feature of cancer cell metabolism and intracellular signalling 
(55). Phospholipase D1, up-regulated (2.1-fold) in zebrafish V12RAS-driven VGP melanocyte neoplasia, which 
removes the choline head group, is essential for HRASG12V-mediated transformation and tumour formation 
(56) and is up-regulated also in human melanoma (57). Thus choline metabolism too emerges as a potential 
target for therapeutic intervention in melanoma.  
 
Although both the DESI-MS and UHPLC-MS use electrospray as the ionisation source, different solvents were 
used for each experiment therefore giving rise to different adducts. In this respect, both similar and different 
lipid species were expected to be detected between the two techniques. Fig. 3C shows DESI-MS images of 
two of the species also seen up-regulated in tumours in the UHPLC-MS analysis (m/z 714.52 and 776.54) as 
well as two PEs that were not detected by UHPLC-MS. The identified species both contain a 
monounsaturated fatty acid, indicating the action of SCD-1, which was revealed to be overexpressed in the 
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transcriptome analysis. UHPLC-MS is able to give a more quantitative analysis compared to DESI-MS, but 
UHPLC-MS cannot give information regarding spatial distribution. Interestingly, DESI-MS imaging revealed 
heterogeneous distributions of phospholipid species in VGP tumours. Positive ion mode images revealed 
lipids with interesting heterogeneity, and are potential PCs, based on database searches using accurate 
mass. However, identification of these lipids is not trivial due to multiple ionisation mechanisms (i.e. the 
addition of a proton, sodium or potassium), and therefore have not been identified in this instance. It is clear 
from this study that lipid metabolism is not a uniform process across the whole tumour, and further studies 
will be needed to elucidate the reasons behind such complexity in melanoma metabolism.  
 
RT-PCR, western blotting and immunohistochemistry revealed LPL expression in a majority of melanoma 
samples, albeit to varying amounts and with varying fractions of positive cells. We hypothesize that at one 
extreme (represented in culture by WM852 and WM1361 cells and potentially in vivo by tumours with 
homogeneous strong LPL expression), melanoma cells depend entirely on LPL for fatty acid supply; while at 
the other end of the spectrum tumour cells are largely independent of LPL for fatty acid provision and may 
even not express LPL (a few primary tumours were identified seemingly lacking LPL expression). These latter 
cells (or even whole tumours) may rely entirely on de novo synthesis, or may express alternative lipases to 
carry out lipolysis. In between are cell populations (represented in culture by WM266-4, WM-35 and A375 
cells) that express LPL for lipolysis and also undertake fatty acid synthesis, either representing a 
heterogeneous mixture of cell types, or with cells possessing both capabilities simultaneously. Coincident 
lipolysis and fatty acid synthesis has previously been described in breast carcinoma, liposarcoma and 
prostate carcinoma cells (58). Proximity to adipose and the availability of exogenous fatty acid has been 
shown to decrease dependency on lipogenesis in melanoma cells, concomitant with decreased sensitivity to 
FASN inhibition (9). Given the capacity of melanoma cells (and other cancer cells) to profit from both lipolytic 
and lipogenic mechanisms, it is desirable to explore strategies to target simultaneously both fatty acid 
scavenging and de novo synthesis. We demonstrated here the potential of an LPL small molecule inhibitor in 
combination with FASN inhibitor; lipid transporters such as FATP family members, FABP7 and CD36 might 
also make for appropriate targets. 
 
In conclusion, zebrafish V12RAS-driven melanocyte tumours were seen to undergo substantial changes to 
their lipid metabolism. Multi-modality imaging combined with lipidome and transcriptome analyses has 
shown that zebrafish V12RAS-driven melanocyte tumours scavenge free fatty acids and upregulate the 
production of certain glycerophospholipids. Key lipid metabolism pathways are well-conserved between 
zebrafish and human and several overlaps between altered lipid metabolism genes in the zebrafish 
melanocyte neoplasia models studied here and human melanoma have been highlighted, supporting the 
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preclinical significance of our zebrafish models. This study demonstrated the complementarity of PET and 
DESI-MS as in vivo and ex vivo imaging modalities respectively that differ in spatial resolution as well as their 
targeted nature. Potentially, detection of fatty acid uptake by PET might be used to locate tumours in 
patients, as well as to stratify patients for treatment with inhibitors of fatty acid scavenging, or to monitor 
therapeutic intervention. The feasibility of [18F]-FTHA PET in humans has already been demonstrated (59), 
albeit not yet for tumour imaging. UHPLC-MS and DESI-MS could be used on biopsy samples, and so also 
have the potential to inform treatments in the clinic. Combining lipidomics and transcriptomics reveals a 
more complete picture of altered tumour lipid metabolism than either alone. While deregulated lipid 
metabolism pathways are promising targets for future therapeutic intervention, the heterogeneous nature 
in which lipid metabolism is altered must also be taken into consideration and combinatorial approaches are 
likely to be more effective than monotherapies. 
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Figure Legends 
 
Fig.1: Transcriptome profiling identifies a gene signature associated with malignant progression. A) The 
four models from which fin or tumour samples were excised and RNA extracted. RGP, radial growth phase. 
VGP, vertical growth phase. B) Bar chart depicting the number of highly significant (P<0.0001, Kruskall 
Wallace test) differentially expressed genes (DEGs) with at least a two-fold difference in expression from 
wild-type in the different models. C) A heat map of gene expression following hierarchal clustering. D) Venn 
diagrams illustrating the extent of overlap in DEGs between the models. E) GO enrichment analysis reveals 
that 19% of DEGs in VGP samples are implicated in metabolism of which lipid metabolism genes represent 
28%. 
 
Fig. 2: PET and DESI-MS imaging of ([18F])-FTHA in wild-type zebrafish and zebrafish bearing melanoma 
tumours. A) [18F]-FTHA PET scans of wild-type zebrafish. B) (Upper panel) Negative ion mode DESI-MS image 
(120 μm spatial resolution) of FTHA distribution in a wild-type zebrafish, overlaid with an optical image. 
(Lower panel) An adjacent section was stained with H&E. C) [18F]-FTHA PET scans of three tumour-bearing 
zebrafish. D) An optical image of one of the zebrafish that underwent PET scanning. E) DESI-MS image of 
FTHA distribution in the whole fish (50 μm resolution) F) DESI-MS image of FTHA distribution in the tail 
tumour (40 μm resolution). Images E and F have been overlaid with an ion appearing only in the skeletal 
muscle (m/z 154.1). G) and H) Corresponding H&E images. Arrows indicate tumours in the fish; this zebrafish 
has an obvious tumour in its tail, and a tumour in its snout which is apparent in the DESI-MS and H&E image.  
 
Fig. 3: Altered glycerophospholipid metabolism accompanies melanocyte neoplasia progression. A) PCA 
analysis from UPLC-MS negative and positive ion modes demonstrates the significant difference between 
samples based on separation by principal component 1 and 2 (PC1 and PC2). QC refers to a pooled biological 
quality control sample run before and every fifth injection during analysis. B) Integration of lipid metabolite 
and lipid metabolism genes for tumour nodules (VGP) using Metscape reveals glycerophospholipid 
metabolism to be the most enriched network. Metabolites are indicated as hexagons and genes as circles. A 
darker colour demonstrates a greater degree of deregulation with the relative size of the symbol indicating 
up or down-regulation.  
(See also http://ndexbio.org/#/network/e22027c9-6dbb-11e8-a4bf-
0ac135e8bacf?accesskey=679ae449f48ae05d9116df1983f201390c539b285cc525ab149f2e178e55717e). C) 
Negative ion mode DESI-MS images of the whole zebrafish, including an overlay with H&E stain where 
tumours have been circled (MS/MS spectra for m/z 720.50 and 734.53 species shown in Supp. Fig. 6A and B 
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respectively). D) Positive ion mode DESI-MS images of unidentified lipids in the tail tumour with 
corresponding H&E stain (left).  
 
Fig. 4: LPL expression in human melanoma cell lines and tumours. A) Real-time PCR quantitation for LPL, 
CD36, FATP1, FATP2 and FABP7 mRNA expression in a panel of melanoma cell lines relative to normal human 
melanocytes (NHM). B) Positive immunohistochemical signal (pink/red) reveals LPL expression in a panel of 
naevi, primary tumours and metastases. -, absent staining; +, weak staining; ++, strong heterogeneous 
staining; +++, strong homogeneous staining. C) Representative image illustrating LPL expression 
(arrowheads) in nests of naevocytes at the epidermal/dermal junction in a compound naevus.  
 
Fig. 5:  LPL contributes to melanoma cell growth. A) A transgenic system for co-expression of LPL and 
V12RAS. Upper panel Uninjected V12RAS; mitfa-/- animal; lower panel V12RAS; mitfa-/- animal injected with 
mitfa-encoding plasmid displaying complete pigment rescue and a tumour nodule (arrow head). B) LPL co-
expression accelerates tumour nodule appearance to the same extent as CCND1. ****, p<0.0001 Log-rank 
(Mantel-Cox) test. C) LPL co-expression accelerates tumour nodule growth **, p<0.01 Kruskal-Wallis test. D) 
Knockdown of LPL using siRNA suppresses cell growth. **, p<0.01; ***, p<0.001 ANOVA. E) Expression of 
FASN mRNA in a panel of melanoma cells relative to normal human melanocytes (NHM) detected by RT-PCR. 
F) Co-treatment of cells with GSK264220A (LPLi) and C75 (FASNi). 
 
Research. 
on February 24, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2409 
Research. 
on February 24, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2409 
Research. 
on February 24, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2409 
Research. 
on February 24, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2409 
Research. 
on February 24, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2409 
Research. 
on February 24, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2409 
 Published OnlineFirst March 12, 2019.Cancer Res 
  
Fiona Henderson, Hannah R Johnston, Andrew P Badrock, et al. 
  
in zebrafish
metabolism accompanies melanocyte neoplasia progression 
Enhanced fatty acid scavenging and glycerophospholipid
  
Updated version
  
 10.1158/0008-5472.CAN-18-2409doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://cancerres.aacrjournals.org/content/suppl/2019/03/12/0008-5472.CAN-18-2409.DC1
Access the most recent supplemental material at:
  
Manuscript
Author
been edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerres.aacrjournals.org/content/early/2019/03/12/0008-5472.CAN-18-2409
To request permission to re-use all or part of this article, use this link
Research. 
on February 24, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2409 
